Dr. Reddy Laboratories heals with impressive Q2 results
Nidhi Jani / 31 Oct 2017
Company has registered 1.1% marginal decline from Global Generics segment mainly on account of lower contribution from North America offset by increased contribution from Europe, India and Emerging Markets.
Dr. Reddy's Laboratories reported good set of numbers for the quarter ended September 30, 2017 on Tuesday.
Total sales for Q2FY18, came in at Rs. 3,559.8 crore. This represents a 6.8 per cent sequential increase and 1.6 per cent YoY decline.
Company has registered 1.1% marginal decline from Global Generics segment mainly on account of lower contribution from North America offset by increased contribution from Europe, India and Emerging Markets.
Operating profit (EBIT) for the recently concluded quarter amounted to Rs. 399.2 crore and the EBIT margin stood at 11.21 per cent. It reported PAT of Rs. 305 crore which represents a sequential 3 fold in PAT and a YoY decline of 1.1 per cent.
The stock Dr. Reddy's Lab opened at Rs. 2,433 per share and touched an intra-day high and low of Rs. 2,504.7 and Rs. 2,390.50 per share, on Tuesday.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.